Ivosidenib for advanced bile duct cancer with IDH1 mutation
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests the drug Ivosidenib for people with advanced bile duct cancer that has a specific genetic change called an IDH1 mutation. It may be an option if you haven't had chemotherapy yet or if your cancer returned more than 6 months after surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a type of bile duct cancer that has spread or cannot be removed by surgery.
- You must have a specific genetic change (IDH1 mutation), confirmed by a genetic test.
- You must be well enough to be up and about (ECOG score 0 or 1) and have a life expectancy of at least 3 months.
- You must not have had Ivosidenib before, and you cannot have ampulla of Vater cancer.
- You must not be pregnant or breastfeeding, and use effective birth control if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, ivonescimab, compared to standard chemotherapy (FOLFOX) for people with advanced bile duct cancer that has progressed after initial treatment. It aims to see if ivonescimab can help control the cancer better.
This trial tests a combination of two chemotherapy drugs and an immunotherapy drug, followed by targeted radiation, in people with bile duct or gallbladder cancer that cannot be removed with surgery. The goal is to see if this approach can shrink tumors and improve outcomes.
This trial tests a new combination of a drug that helps your immune system fight cancer, called sintilimab, along with chemotherapy. It is for people who have bile duct cancer or gallbladder cancer that has spread to other parts of the body and have not had treatment for this stage yet. The goal is to see if this combination helps shrink tumors or stops them from growing.
This trial tests a targeted pill called ivosidenib for people with a specific type of bile duct cancer (IDH1-mutated) who have completed surgery and chemotherapy. The goal is to see if taking ivosidenib as a maintenance therapy helps keep the cancer from coming back.
This study is looking at how well the drug ivosidenib works for people with a certain type of bile duct cancer (cholangiocarcinoma) that has a specific change in the IDH1 gene. It is for people whose cancer has spread or cannot be removed by surgery and who have already tried at least one other cancer treatment.
This trial tests an oral drug (ivosidenib) for people with IDH1-mutated cancers who also have liver or kidney problems. It aims to find the right dose and see how safe and effective it is for these patients.
Hear when a new Biliary Tract Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.